Cargando…

Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer

BACKGROUND: (99m)Tc-Rituximab is a new specific radiopharmaceutical that binds to the CD20 receptor which is highly expressed on the surface of B cells. We conducted a study in which (99m)Tc-Rituximab was compared with filtered (99m)Tc-sulfur colloid (fTcSC) for sentinel lymph node (SLN) detection i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing-Jie, Zhang, Wan-Chun, An, Cai-Xia, Li, Xiao-Min, Ma, Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794795/
https://www.ncbi.nlm.nih.gov/pubmed/31615471
http://dx.doi.org/10.1186/s12885-019-6197-9
_version_ 1783459364149919744
author Zhang, Jing-Jie
Zhang, Wan-Chun
An, Cai-Xia
Li, Xiao-Min
Ma, Le
author_facet Zhang, Jing-Jie
Zhang, Wan-Chun
An, Cai-Xia
Li, Xiao-Min
Ma, Le
author_sort Zhang, Jing-Jie
collection PubMed
description BACKGROUND: (99m)Tc-Rituximab is a new specific radiopharmaceutical that binds to the CD20 receptor which is highly expressed on the surface of B cells. We conducted a study in which (99m)Tc-Rituximab was compared with filtered (99m)Tc-sulfur colloid (fTcSC) for sentinel lymph node (SLN) detection in patients with breast cancer. METHOD: The study is divided into three parts. 1. Initially, 25 patients were selected for an internal controlled trial to received both (99m)Tc-Rituximab and fTcSC, the interval time is separated by ≥2 days. 2. Then, 91 patients were selected for a randomized controlled trial (41 and 50 patients in the (99m)Tc-Rituximab and fTcSC groups, respectively). All patients were administered either agent at the 6- and 12-o’ clock positions by subareolar injection technique. SLN mapping was then performed 2 h after injection. 3. Serial dynamic images were further acquired for 2 h in 31 patients (22 and 9 patients from (99m)Tc-Rituximab and fTcSC cohorts, respectively). RESULTS: The identification rate of lymphoscintigraphy and SLNB in all and axilla regions for (99m)Tc-Rituximab and (99m)Tc-SC were 98.5% vs 98.7, 100% vs 98.4%, respectively. The mean number of SLNs identified by (99m)Tc-Rituximab and fTcSC was respectively 2.72 and 3.28, with a significant difference of P = 0.013 (paired sample t-test). The difference exists in the internal mammary and clavicular area, not in the axillary. The mean number of axillary sentinel lymph node biopsy (SLNB) for (99m)Tc-Rituximab and fTcSC was 2.95 vs 3.14, respectively, and no significant difference existed. (99m)Tc-Rituximab also exhibited a significantly faster injection site clearance rate when compared with fTcSC (0.193 ± 0.057 h(− 1) vs 0.021 ± 0.007 h(− 1), respectively). CONCLUSION: No significant difference was observed in identification rate and number of axillary SLN imaging and SLNB, between the two tracers. Compared to fTcSC, (99m)Tc-Rituximab based imaging demonstrated a fewer number of secondary lymph nodes and had faster injection site clearance rate. TRIAL REGISTRATION: www.chictr.org.cn, ChiCTR1900024990 (retrospectively registered August 6, 2019).
format Online
Article
Text
id pubmed-6794795
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67947952019-10-21 Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer Zhang, Jing-Jie Zhang, Wan-Chun An, Cai-Xia Li, Xiao-Min Ma, Le BMC Cancer Research Article BACKGROUND: (99m)Tc-Rituximab is a new specific radiopharmaceutical that binds to the CD20 receptor which is highly expressed on the surface of B cells. We conducted a study in which (99m)Tc-Rituximab was compared with filtered (99m)Tc-sulfur colloid (fTcSC) for sentinel lymph node (SLN) detection in patients with breast cancer. METHOD: The study is divided into three parts. 1. Initially, 25 patients were selected for an internal controlled trial to received both (99m)Tc-Rituximab and fTcSC, the interval time is separated by ≥2 days. 2. Then, 91 patients were selected for a randomized controlled trial (41 and 50 patients in the (99m)Tc-Rituximab and fTcSC groups, respectively). All patients were administered either agent at the 6- and 12-o’ clock positions by subareolar injection technique. SLN mapping was then performed 2 h after injection. 3. Serial dynamic images were further acquired for 2 h in 31 patients (22 and 9 patients from (99m)Tc-Rituximab and fTcSC cohorts, respectively). RESULTS: The identification rate of lymphoscintigraphy and SLNB in all and axilla regions for (99m)Tc-Rituximab and (99m)Tc-SC were 98.5% vs 98.7, 100% vs 98.4%, respectively. The mean number of SLNs identified by (99m)Tc-Rituximab and fTcSC was respectively 2.72 and 3.28, with a significant difference of P = 0.013 (paired sample t-test). The difference exists in the internal mammary and clavicular area, not in the axillary. The mean number of axillary sentinel lymph node biopsy (SLNB) for (99m)Tc-Rituximab and fTcSC was 2.95 vs 3.14, respectively, and no significant difference existed. (99m)Tc-Rituximab also exhibited a significantly faster injection site clearance rate when compared with fTcSC (0.193 ± 0.057 h(− 1) vs 0.021 ± 0.007 h(− 1), respectively). CONCLUSION: No significant difference was observed in identification rate and number of axillary SLN imaging and SLNB, between the two tracers. Compared to fTcSC, (99m)Tc-Rituximab based imaging demonstrated a fewer number of secondary lymph nodes and had faster injection site clearance rate. TRIAL REGISTRATION: www.chictr.org.cn, ChiCTR1900024990 (retrospectively registered August 6, 2019). BioMed Central 2019-10-15 /pmc/articles/PMC6794795/ /pubmed/31615471 http://dx.doi.org/10.1186/s12885-019-6197-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhang, Jing-Jie
Zhang, Wan-Chun
An, Cai-Xia
Li, Xiao-Min
Ma, Le
Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer
title Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer
title_full Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer
title_fullStr Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer
title_full_unstemmed Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer
title_short Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer
title_sort comparative research on (99m)tc-rituximab and (99m)tc-sulfur colloid in sentinel lymph node imaging of breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794795/
https://www.ncbi.nlm.nih.gov/pubmed/31615471
http://dx.doi.org/10.1186/s12885-019-6197-9
work_keys_str_mv AT zhangjingjie comparativeresearchon99mtcrituximaband99mtcsulfurcolloidinsentinellymphnodeimagingofbreastcancer
AT zhangwanchun comparativeresearchon99mtcrituximaband99mtcsulfurcolloidinsentinellymphnodeimagingofbreastcancer
AT ancaixia comparativeresearchon99mtcrituximaband99mtcsulfurcolloidinsentinellymphnodeimagingofbreastcancer
AT lixiaomin comparativeresearchon99mtcrituximaband99mtcsulfurcolloidinsentinellymphnodeimagingofbreastcancer
AT male comparativeresearchon99mtcrituximaband99mtcsulfurcolloidinsentinellymphnodeimagingofbreastcancer